Stocks · News reference
Krystal Biotech Files Response With USPTO on KB801 Patent Application; Discontinues Clinical Study To Advance KB801 Into Pivotal Trial; No Safety Concerns Observed; No Further Subject-level Updates From Discontinued Study; Pivotal Trial Results Expected In Due Course
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001711279/000171127926000050/krys-20260721.htm
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 21, 2026, 9:33 PM
- Checked
- Jul 21, 2026, 9:33 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386
Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.
Read original at benzingaKrystal Biotech shares are trading lower after the company announced mixed Q2 financial results.
Read original at benzinga8-K filing — Krystal Biotech, Inc. (KRYS)
Filed: 2026-08-03 AccNo: 0001711279-26-000058 Size: 587 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar